Short answer · Medically reviewed summary · Last updated: 2026-04-07
Multiple Endocrine Neoplasia (MEN) is a group of rare, inherited disorders that cause tumors in endocrine glands, with an estimated prevalence ranging from 1 in 30,000 to 1 in 40,000 for MEN1 and approximately 1 in 35,000 for MEN2. Because these conditions are often underdiagnosed or misdiagnosed until symptoms become severe, these figures are considered estimates rather than precise population counts. Is Multiple Endocrine Neoplasia considered a rare disease? Yes, Multiple Endocrine Neoplasia is classified as a rare disease.
1 people with Multiple Endocrine Neoplasia have shared their first-person experience on this question at DiseaseMaps.
What is the prevalence of Multiple Endocrine Neoplasia?
Prevalence of Multiple Endocrine Neoplasia: how many people are affected worldwide, differences by sex and region, with sources.
Multiple Endocrine Neoplasia (MEN) is a group of rare, inherited disorders that cause tumors in endocrine glands, with an estimated prevalence ranging from 1 in 30,000 to 1 in 40,000 for MEN1 and approximately 1 in 35,000 for MEN2. Because these conditions are often underdiagnosed or misdiagnosed until symptoms become severe, these figures are considered estimates rather than precise population counts.
Is Multiple Endocrine Neoplasia considered a rare disease?
Yes, Multiple Endocrine Neoplasia is classified as a rare disease. Because these conditions are autosomal dominant genetic disorders, they are not spread through environmental factors but are passed down through families. While the exact prevalence of Multiple Endocrine Neoplasia varies by specific subtype (MEN1, MEN2A, and MEN2B), all are considered rare conditions that require specialized endocrine and genetic care. At DiseaseMaps.org, we currently support a community of 137 individuals living with Multiple Endocrine Neoplasia, providing a unique, real-world perspective on the daily challenges of living with this rare diagnosis.
What do we know about the incidence and gender distribution of Multiple Endocrine Neoplasia?
Data on the annual incidence of Multiple Endocrine Neoplasia is limited, but it is generally understood that the condition affects males and females with equal frequency. Because the genetic mutations responsible for the disease are located on autosomal chromosomes, there is no sex-linked bias in inheritance. However, clinical presentation can sometimes be delayed in one gender due to hormonal influences or differences in how tumors are detected during routine screenings. Epidemiologists emphasize that the "true" incidence is likely higher than reported, as many individuals may remain asymptomatic for years or receive a diagnosis only after a related tumor—such as a parathyroid or pancreatic tumor—is discovered incidentally.
How does age of onset affect the prevalence of Multiple Endocrine Neoplasia?
The age of onset for Multiple Endocrine Neoplasia varies significantly based on the specific type of mutation:
- MEN1: Symptoms typically manifest in early adulthood, though biochemical evidence of endocrine activity can often be detected in adolescents.
- MEN2A: Clinical symptoms often appear in young adulthood, though medullary thyroid carcinoma (MTC) can occur in childhood.
- MEN2B: This is the most aggressive form; symptoms often appear in early childhood, necessitating early genetic testing and, in some cases, prophylactic surgery.
Due to the hereditary nature of Multiple Endocrine Neoplasia, the prevalence is often tracked within families through cascade screening, where relatives of a newly diagnosed patient are tested for the same genetic mutation.
Why is it difficult to track the exact number of people with Multiple Endocrine Neoplasia?
Accurate prevalence data for Multiple Endocrine Neoplasia is hindered by several factors. First, the disease is highly heterogeneous; a patient may have one endocrine tumor for years before other tumors develop, leading to fragmented medical records. Second, individuals in rural or underserved areas may not have access to the specialized genetic testing required for a definitive diagnosis. Consequently, many people live with the condition without knowing their underlying genetic status. The community data at DiseaseMaps.org highlights this reality, as our 137 members often report long "diagnostic odysseys" before receiving their official classification.
Next steps
- Consult an endocrinologist or clinical geneticist to discuss genetic testing if you have a family history of endocrine tumors.
- Join the DiseaseMaps.org Multiple Endocrine Neoplasia community to connect with others who understand the diagnostic process.
- Maintain a detailed log of your endocrine health, including blood tests (calcium, parathyroid hormone, calcitonin) and imaging results.
- Ask your physician about "cascade screening" to identify other family members who may be at risk.
Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment from a qualified healthcare provider.
References
- NIH Genetic and Rare Diseases (GARD) Information Center: Multiple Endocrine Neoplasia.
- Orphanet: Rare Disease Database (ORPHA:2472).
- OMIM (Online Mendelian Inheritance in Man): Multiple Endocrine Neoplasia Type 1 (#131100).
- American Association of Clinical Endocrinology (AACE) Clinical Practice Guidelines for Endocrine Neoplasia.
Posted Oct 25, 2017 by Mrcperk 2000
